Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Near term planning for the globalisation of Penthrox

May 8, 2015Cathy WilsonNews

8 May 2015

ASX ANNOUNCEMENT

Near term planning for the globalisation of Penthrox

The approval of Penthrox for use in the United Kingdom, France, Belgium and Ireland validates our Regulatory Dossier and the clinical and safety data we have obtained for Penthrox.  It proves Penthrox is a ‘world class’ product which regulatory authorities around the world can approve for sale.

With the successful closure of the Decentralised Procedure (DP) and ultimate approval in Europe, MVP plans to aggressively expand the number of countries which can sell Penthrox:

For more information click on the link: ASX Announcement – Near term planning for the globalisation of Penthrox

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Green Whistle gets the Green Light – FDA clears US Penthrox clinical trial

    2 March 2022 ASX ANNOUNCE...

  • MVP FY22 Half Year Results Investor Presentation

    25 February 2022 ASX anno...

  • MVP FY22 Half Year Report and Accounts

    24 February 2022 ASX Anno...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me

Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: [email protected]
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: [email protected]

Email Newsletter